Results further emphasize the value of the AFFITOPE® technology platform for potential first-in-class immunotherapies against a range of chronic non-communicable disease indications VIENNA, Austria, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A once-daily oral PCSK9 inhibitor reduced LDL in ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...

PHILADELPHIA, PA—For high-risk patients with heterozygous familial hypercholesterolemia (HeFH), a novel therapy that shuts off the PCSK9 gene can lower LDL cholesterol, early data from the heart-1 ...

PCSK9 inhibitors typically are used to pursue cholesterol-reduction indications. But a new deal from Novartis ($NVS) outlicenses its Phase II-ready, anti-PCSK9 ...

Epitope information is increasingly being used to understand the mechanism of action (MoA) of therapeutic monoclonal antibodies (mAbs), as well as to overcome the mounting challenges of patenting them ...

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of ...

Merck & Co. has completed a hat trick of phase 3 victories for its oral PCSK9 inhibitor. Navigating into the broader hyperlipidemia population, the drugmaker stayed out of the shoals and charted a ...

Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response AT04A ...